Tocagen Licenses Greater China Rights for Phase III Cancer Immunotherapy to ApolloBio – Genetic Engineering & Biotechnology News
|
Tocagen Licenses Greater China Rights for Phase III Cancer Immunotherapy to ApolloBio
Genetic Engineering & Biotechnology News Tocagen has granted ApolloBio exclusive rights to its Phase III two-part cancer immunotherapy candidate Toca 511 (vocimagene amiretrorepvec) and Toca FC in the greater China region, in a deal that could generate up to $127 million-plus for Tocagen … |
